載入中
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
前收盤價
US$5.35
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
53
多空交錯
風險
69
高風險
動能
39
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
日內區間
目前US$5.35
52週區間
目前US$5.35
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 3306 USD | 4134 USD | 1.18萬 USD | 1.31萬 USD |
| 毛利 | — | −3306 USD | −4134 USD | −1.18萬 USD | −1.31萬 USD |
| 研究與開發 | 977.19萬 USD | 929.01萬 USD | 1409.56萬 USD | 930.01萬 USD | 980.51萬 USD |
| 銷售、一般及管理費用 | 621.46萬 USD | 560.85萬 USD | 476.95萬 USD | 562.12萬 USD | 466.78萬 USD |
| 營業費用 | 1598.66萬 USD | 1489.86萬 USD | 1886.1萬 USD | 1492.12萬 USD | 1447.28萬 USD |
| 利息收入 | 15.38萬 USD | 6.03萬 USD | 2.77萬 USD | — | 9.29 USD |
| 利息支出 | 1.52萬 USD | 1.61萬 USD | 1.38萬 USD | 7027 USD | 9285 USD |
| 折舊和攤銷 | 3918 USD | 3306 USD | 4134 USD | 1.18萬 USD | 1.31萬 USD |
| 營業利益 | −1598.66萬 USD | −1490.19萬 USD | −1886.51萬 USD | −1493.3萬 USD | −1448.59萬 USD |
| 淨利 | −1585.06萬 USD | −1485.78萬 USD | −1885.12萬 USD | −1527.41萬 USD | −1449.52萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$0.50
下跌空間 90.65%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年7月22日 | 1:12 | — | — |
股票分割 | 2025年2月21日 | 1:50 | — | — |
股票分割 | 2024年6月5日 | 1:50 | — | — |
股票分割 | 2022年11月29日 | 1:30 | — | — |
已生效 2025年7月22日
1:12
已生效 2025年2月21日
1:50
已生效 2024年6月5日
1:50
已生效 2022年11月29日
1:30
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
